Literature DB >> 2508544

Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against Mycobacterium tuberculosis?

L B Heifets1, M A Flory, P J Lindholm-Levy.   

Abstract

The commonly accepted hypothesis explaining the mechanism of action of pyrazinamide (PZA) is based on the assumption that PZA-susceptible Mycobacterium tuberculosis strains produce pyrazinamidase, which hydrolyzes PZA to the antibacterial moiety pyrazinoic acid (POA). It is not clear whether POA has specific antimicrobial activity or the inhibition of growth caused by POA is due to its ability to lower the pH of the environment below the limits of tolerance of M. tuberculosis growth. We confirmed in this study that POA, depending on the concentration, lowered the pH of 7H12 broth (pH 6.0), which ranged from 5.8 at 120.0 micrograms/ml to 4.6 at 960.0 micrograms/ml. Therefore, we tested the inhibitory effects of different concentrations of POA in broth in which the final pH was adjusted to 5.6 by adding appropriate amounts of phosphoric acid or dipotassium phosphate. Under these conditions, we found a clear dose-response correlation, proving that POA does have specific antimicrobial activity. The MIC of POA at pH 5.6 was 240 to 480 micrograms/ml, 8- to 16-fold higher than the MIC of PZA under the same conditions and much higher than the concentrations achievable in humans. This suggests that the action of POA in an acid environment is a combined effect of its specific activity and its ability to lower the pH below the limits of tolerance of the target organism.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2508544      PMCID: PMC172635          DOI: 10.1128/AAC.33.8.1252

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  [Type differentiation of tuberculosis bacteria with the aid of the nicotinamidase test].

Authors:  R BONICKE; B P LISBOA
Journal:  Tuberkulosearzt       Date:  1959-06

2.  Activation of pyrazinamide and nicotinamide in acidic environments in vitro.

Authors:  W McDERMOTT; R TOMPSETT
Journal:  Am Rev Tuberc       Date:  1954-10

3.  Pyrazinamide susceptibility and amidase activity of tubercle bacilli.

Authors:  K Konno; F M Feldmann; W McDermott
Journal:  Am Rev Respir Dis       Date:  1967-03

4.  Absorption, metabolism and excretion of pyrazinamide in man.

Authors:  G A Ellard
Journal:  Tubercle       Date:  1969-06

5.  [Effect of pyrazinamide on pH of cytoplasm sections surrounding phagocytized Mycobacteria].

Authors:  E P Pavlov; E G Tushov; G A Koniaev
Journal:  Probl Tuberk       Date:  1974

6.  Observations in vitro on the suitability of pyrazinamide for intermittent chemotherapy of tuberculosis.

Authors:  J M Dickinson; D A Mitchison
Journal:  Tubercle       Date:  1970-12

7.  Radiometric method for testing susceptibility of mycobacteria to pyrazinamide in 7H12 broth.

Authors:  L B Heifets; M D Iseman
Journal:  J Clin Microbiol       Date:  1985-02       Impact factor: 5.948

8.  Successful intermittent treatment of smear-positive pulmonary tuberculosis in six months: a cooperative study in Poland.

Authors:  D E Snider; J Rogowski; M Zierski; E Bek; M W Long
Journal:  Am Rev Respir Dis       Date:  1982-02

9.  Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method.

Authors:  M Salfinger; L B Heifets
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

  9 in total
  16 in total

Review 1.  Modes and modulations of antibiotic resistance gene expression.

Authors:  Florence Depardieu; Isabelle Podglajen; Roland Leclercq; Ekkehard Collatz; Patrice Courvalin
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

Review 2.  Molecule Property Analyses of Active Compounds for Mycobacterium tuberculosis.

Authors:  Vadim Makarov; Elena Salina; Robert C Reynolds; Phyo Phyo Kyaw Zin; Sean Ekins
Journal:  J Med Chem       Date:  2020-04-20       Impact factor: 7.446

3.  Comparing and Validating Machine Learning Models for Mycobacterium tuberculosis Drug Discovery.

Authors:  Thomas Lane; Daniel P Russo; Kimberley M Zorn; Alex M Clark; Alexandru Korotcov; Valery Tkachenko; Robert C Reynolds; Alexander L Perryman; Joel S Freundlich; Sean Ekins
Journal:  Mol Pharm       Date:  2018-04-26       Impact factor: 4.939

4.  Expression of Mycobacterium smegmatis pyrazinamidase in Mycobacterium tuberculosis confers hypersensitivity to pyrazinamide and related amides.

Authors:  H I Boshoff; V Mizrahi
Journal:  J Bacteriol       Date:  2000-10       Impact factor: 3.490

5.  Pyrazinamide, but not pyrazinoic acid, is a competitive inhibitor of NADPH binding to Mycobacterium tuberculosis fatty acid synthase I.

Authors:  Halimah Sayahi; Oren Zimhony; William R Jacobs; Alexander Shekhtman; John T Welch
Journal:  Bioorg Med Chem Lett       Date:  2011-06-29       Impact factor: 2.823

Review 6.  Antimicrobial agent resistance in mycobacteria: molecular genetic insights.

Authors:  J M Musser
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

7.  Activity of pyrazinamide in a murine model against Mycobacterium tuberculosis isolates with various levels of in vitro susceptibility.

Authors:  S P Klemens; C A Sharpe; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

8.  Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide.

Authors:  R J Speirs; J T Welch; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

9.  In vitro antimycobacterial activities of pyrazinamide analogs.

Authors:  S Yamamoto; I Toida; N Watanabe; T Ura
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

10.  Evaluation of methods for testing the susceptibility of clinical Mycobacterium tuberculosis isolates to pyrazinamide.

Authors:  Zhenling Cui; Jie Wang; Junmei Lu; Xiaochen Huang; Ruijuan Zheng; Zhongyi Hu
Journal:  J Clin Microbiol       Date:  2013-02-06       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.